Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 261

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated

Open access
Maas, Sybren L. N., Stichel, Damian, Hielscher, Thomas, Sievers, Philipp, Berghoff, Anna S., Schrimpf, Daniel, Sill, Martin, Euskirchen, Philipp, Blume, Christina, Patel, Areeba, Dogan, Helin, Reuss, David, Dohmen, Hildegard, Stein, Marco, Reinhardt, Annekathrin, Suwala, Abigail K., Wefers, Annika K., Baumgarten, Peter, Ricklefs, Franz, Rushing, Elisabeth J., Bewerunge-Hudler, Melanie, Ketter, Ralf, Schittenhelm, Jens, Jaunmuktane, Zane, Leu, Severina, Greenway, Fay E. A., Bridges, Leslie R., Jones, Timothy, Grady, Conor, Serrano, Jonathan, Golfinos, John, Sen, Chandra, Mawrin, Christian, Jungk, Christine, Hänggi, Daniel, Westphal, Manfred, Lamszus, Katrin, Etminan, Nima, Jungwirth, Gerhard, Herold-Mende, Christel, Unterberg, Andreas, Harter, Patrick N., Wirsching, Hans-Georg, Neidert, Marian C., Ratliff, Miriam, Platten, Michael, Snuderl, Matija, Aldape, Kenneth D., Brandner, Sebastian, Hench, Jürgen, Frank, Stephan, Pfister, Stefan M., Jones, David T. W., Reifenberger, Guido, Acker, Till, Wick, Wolfgang, Weller, Michael, Preusser, Matthias, von Deimling, Andreas, Sahm, Felix, For the German Consortium on Aggressive Meningiomas (KAM)·2021·Journal of Clinical Oncology

Abstract

PURPOSE: Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tumors are established ( CDKN2A/B and TERT), whereas no molecularly based stratification exists for the broad spectrum of patients with low- and intermediate-risk meningioma. METHODS: DNA methylation data and copy-number information were generated for 3,031 meningiomas (2,868 patients), and mutation data for 858 samples. DNA methylation subgroups, copy-number variations (CNVs), mutations, and WHO grading were analyzed. Prediction power for outcome was assessed in a retrospective cohort of 514 patients, validated on a retrospective cohort of 184, and on a prospective cohort of 287 multicenter cases. RESULTS: Both CNV- and methylation family–based subgrouping independently resulted in increased prediction accuracy of risk of recurrence compared with the WHO classification (c-indexes WHO 2016, CNV, and methylation family 0.699, 0.706, and 0.721, respectively). Merging all risk stratification approaches into an integrated molecular-morphologic score resulted in further substantial increase in accuracy (c-index 0.744). This integrated score consistently provided superior accuracy in all three cohorts, significantly outperforming WHO grading (c-index difference P = .005). Besides the overall stratification advantage, the integrated score separates more precisely for risk of progression at the diagnostically challenging interface of WHO grade 1 and grade 2 tumors (hazard ratio 4.34 [2.48-7.57] and 3.34 [1.28-8.72] retrospective and prospective validation cohorts, respectively). CONCLUSION: Merging these layers of histologic and molecular data into an integrated, three-tiered score significantly improves the precision in meningioma stratification. Implementation into diagnostic routine informs clinical decision making for patients with meningioma on the basis of robust outcome prediction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.00784

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 261

Metadata

Authors
Maas, S. L. N., Stichel, D., Hielscher, T., Sievers, P., Berghoff, A. S., Schrimpf, D., Sill, M., Euskirchen, P., Blume, C., Patel, A., Dogan, H., Reuss, D., Dohmen, H., Stein, M., Reinhardt, A., Suwala, A. K., Wefers, A. K., Baumgarten, P., Ricklefs, F., Rushing, E. J., Bewerunge-Hudler, M., Ketter, R., Schittenhelm, J., Jaunmuktane, Z., Leu, S., Greenway, F. E. A., Bridges, L. R., Jones, T., Grady, C., Serrano, J., Golfinos, J., Sen, C., Mawrin, C., Jungk, C., Hänggi, D., Westphal, M., Lamszus, K., Etminan, N., Jungwirth, G., Herold-Mende, C., Unterberg, A., Harter, P. N., Wirsching, H.-G., Neidert, M. C., Ratliff, M., Platten, M., Snuderl, M., Aldape, K. D., Brandner, S., Hench, J., Frank, S., Pfister, S. M., Jones, D. T. W., Reifenberger, G., Acker, T., Wick, W., Weller, M., Preusser, M., von Deimling, A., Sahm, F., & For the German Consortium on Aggressive Meningiomas (KAM)
Venue
Journal of Clinical Oncology
Published
2021-12-01
Volume
39
Issue
34
Pages
3839-3852
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3201807042
Cited by
261
References
24
FWCI
24.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. https://app.cochat.ai/papers/10.1200/jco.21.00784
The paper
Maas, S. L. N., Stichel, D., Hielscher, T., Sievers, P., Berghoff, A. S., Schrimpf, D., Sill, M., Euskirchen, P., Blume, C., Patel, A., Dogan, H., Reuss, D., Dohmen, H., Stein, M., Reinhardt, A., Suwala, A. K., Wefers, A. K., Baumgarten, P., Ricklefs, F., . . . For the German Consortium on Aggressive Meningiomas (KAM). (2021). Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.00784

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.